Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry

The commenter is an independent pharmaceutical consultant who suggests clarifying the draft guidance to explicitly recommend updating risk assessments as new information is uncovered during investigations. They argue that the current text lacks actionable instructions for this specific step and provide a proposed revision to ensure firms assess newly identified risks to patient safety and drug quality.

Czarina Vea, a Quality Control Professional, supports the draft guidance but suggests several modifications to improve its effectiveness. The commenter proposes a "Two-Phase" reporting structure for complex observations to balance the 15-business-day deadline with thorough investigation requirements, recommends requiring a consultant's Scope of Work, and suggests a "Dual-Signatory Anchor" approach for executive and quality unit oversight.